Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of ...

A US appeals court has ruled that Regeneron and Sanofi’s Praluent can stay on the market while they appeal a patent case from rival Amgen that blocked them from selling it. Last month ...

Praluent, a PCSK9 inhibitor, was developed by Regeneron (REGN) and Sanofi (SNY) under a global collaboration agreement. The medication is currently indicated to treat both children and adults with ...

Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down to 182 mg/dL. Although I don’t have many side effects, it is very expensive.

Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down to 182 mg/dL. Although I don't have many side effects, it is very expensive.My ...

Regeneron records net product sales of Praluent in the United States and Sanofi does the same outside the country. SNY pays REGN a royalty on such sales. Regeneron records global net product sales ...

Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down to 182 mg/dL. Although I don’t have many side effects, it is very expensive.